Inzy earnings
Web24 mrt. 2024 · INZY support price is $3.10 and resistance is $3.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INZY stock will trade within this expected range on the day.
Inzy earnings
Did you know?
WebFor their last quarter, Inozyme Pharma (INZY) reported earnings of -$0.38 per share, beating the Zacks Consensus Estimate of $-0.43 per share. This reflects a positive … Web9 apr. 2024 · Earnings Growth. Earnings for Inozyme Pharma are expected to grow in the coming year, from ($1.77) to ($1.76) per share. Price to Earnings Ratio vs. the Market. …
Web16 mrt. 2024 · This suggests that analysts have very recently bumped up their estimates for INZY, giving the stock a Zacks Earnings ESP of +12.11% heading into earnings season. Inozyme Pharma, Inc. Price... Web27 mrt. 2024 · Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Equities researchers at Wedbush upped their Q1 2024 earnings estimates for shares of Inozyme Pharma in a report issued on Wednesday, March 22nd.
Web20 feb. 2024 · INZY has an estimated long-term growth rate of 16.6%. Inozyme Pharma’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, with the average surprise ... Web5 uur geleden · BOSTON, April 14, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. I INZY, a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company’s senior vice president and chief …
WebInozyme Pharma Inc. analyst ratings, historical stock prices, earnings estimates & actuals. INZY updated stock price target summary. Dow Jones, a News Corp company About WSJ
Web11 apr. 2024 · BOSTON, April 11, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman … the postnational constellationsWebInozyme (INZY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. GlobeNewswire. Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference. BOSTON, March 01, 2024 (GLOBE NEWSWIRE) ... the post navigationWebInozyme Pharma, Inc. (INZY) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.67 +0.74 (+14.89%) At close: 04:00PM EDT. 5.67 0.00 (0.00%) … siemens breakers catalogWebEarnings Summary For their last quarter, Inozyme Pharma (INZY) reported earnings of -$0.38 per share, beating the Zacks Consensus Estimate of $-0.43 per share. This reflects a positive... the postnational constellation habermasWeb12 apr. 2024 · Shares of Lithia Motors stock opened at $227.63 on Wednesday. The firm has a market capitalization of $6.22 billion, a P/E ratio of 5.17, a price-to-earnings-growth ratio of 1.51 and a beta of 1. ... the post newspaper facebookWebYou can buy and sell Inozyme Pharma (INZY) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. … the post newspaper brunswickWeb11 apr. 2024 · NASDAQ:INZY Inozyme Pharma - INZY Price Target & Analyst Ratings $5.67 +0.74 (+15.01%) (As of 04/6/2024 12:00 AM ET) Compare Today's Range $4.88 $6.20 50-Day Range $2.20 $5.73 52-Week Range $0.99 $6.20 Volume 2.41 million shs Average Volume 1.05 million shs Market Capitalization $247.89 million P/E Ratio N/A … the post newspaper delivery